Continuing their decline from last week, European equities traded in the US as American depositary receipts were sharply lower late Monday morning, falling 1.73% to 1,257.11 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by furniture maker Natuzzi (NTZ) and biopharmaceutical company DBV Technologies (DBVT), which climbed 6.5% and 5.7%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Grifols (GRFS), which increased 1.7% and 0.7%, respectively.
The decliners from continental Europe were led by oil and gas company Eni (E) and pharmaceutical company Ascendis Pharma (ASND), which dropped 5.6% and 3.8%, respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and consumer goods company Unilever (UL), which were down 3.7% each.
From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics (AKTX) and software firm Endava (DAVA), which rose 6.5% and 4.9%, respectively. They were followed by mining company BHP Group (BHP) and pharmaceutical company Silence Therapeutics (SLN), which were up 1.9% and 1.2%, respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and pharmaceutical company AstraZeneca (AZN), which lost 6.2% and 5.4%, respectively. They were followed by pharmaceutical companies GSK (GSK) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which fell 5.3% and 5.2%, respectively.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。